Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. The NEORISK Study.

NCT06441240 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT06441240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. The NEORISK Study.
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2023
Completion date
March 30, 2026
Enrollment
933 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy effect, recurrence, local neoplasm, risk factors, triple negative breast cancer